We are incredibly thankful to our judges for taking the time to participate in this programme.
Applications are reviewed by a panel and judged according to a set of judging criteria. Any conflicts of interest are declared by the judges. If a judge has a conflict, he or she is excluded from any discussions that pertain to the conflict. The judging panel comprises of Intercept representatives from Corporate and Medical Affairs, alongside external advisors representing the perspectives of the medical and patient communities. Applicants will be notified of the outcome of their application by January 2020.
Hanns-Ulrich Marschall, MD, PhD, MSc
Hanns-Ulrich Marschall, MD, PhD, MSc, has been Professor of Clinical Hepatology at Gothenburg University since 2010. He was Professor of Medical Gastroentology and Hepatology at the Karolinska Institute in Stockholm from 2007 to 2010.
He is a leading expert in bile acid metabolism and his research involves animal and human studies with a focus on the interaction between bile acids and the gut microbiota at the Wallenberg Laboratory.
He is also actively involved in a large number of sponsored and investigator-initiated clinical trials focusing on the development of new treatment options for non-alcoholic fatty liver disease/steatohepatitis and cholestatic liver diseases, such as primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC) and in particular, intrahepatic cholestasis of pregnancy (ICP).
Marco Marzioni, MD (EASL representative)
Marco Marzioni, MD, is a clinical gastroenterologist and hepatologist, and Professor of Gastroenterology at the Clinic of Gastroenterology, Università Politecnica delle Marche – “Ospedali Riuniti” University Hospital of Ancona, Italy. He has taught there since 2005.
From 2013 to 2016 he has been a member of the Associazione Italiana Studio Fegato (AISF) Governing Board; from 2014 to 2016 he served as Secretary General of the association. Since 2015, he has been advisor for gastroenterology and hepatology of the Italian Medicine Agency (AIFA).
His research activity focuses on the pathophysiology of liver injury. In particular, his major interest is the study of the mechanism of regulation of cholangiocyte cell biology, injury, and repair. To date, his research activity came out in 105 original articles in major hepatological and gastroenterological international journals. He is a member of the European Association for the Study of the Liver’s (EASL) medical board and acts as the EASL representative judge.
Robert Mitchell-Thain trained in counselling and coaching techniques and is the Head of Education and Development for the PBC Foundation, an international patient organisation based in the United Kingdom.
The Foundation provides support for people living with primary biliary cholangitis (PBC), their families, and friends. Robert is not only a strong advocate on behalf of all liver patients, but he also functions as an information provider to patients calling the helpline, medical professionals, politicians, industry members, and to the general public.
In 2003, he joined the Foundation due to his mother being diagnosed with PBC in 1994. Since then he has presented all around the world to and on behalf of those affected by PBC. His motivation remains his experience with his mother, who had her life transformed once she had the information needed to come to terms with her condition.
Achim Kautz is co-chair of the German liver disease project company Leberhilfe Projekt gUG, which focuses on public policy projects in liver disease.
Achim has a degree in communications science, advertising, and marketing and was the CEO of the Deutsche Leberhilfe e.V. before transferring into his role at Leberhilfe Projekt gUG. He is a founding member of the European Liver Patients’ Association (ELPA) and also held the position of Policy Director at ELPA.
Additionally, Achim is a founding member of the World Hepatitis Alliance (WHA) and is one of its Special Consultants. He also works with the National Strategy Planning Group, an entity brought to life by the World Health Organization, and as an external expert for the Organisation for Economic Co-operation and Development.